Goldman Sachs disclosed Shire PLC (LON:SHP), supporting its price target at 6,300.00GBX earlier today
- Updated: October 1, 2016
Reporting a potential upside of 0.23%, Goldman Sachs hold steady the target price of Shire PLC (LON:SHP) at 6,300.00GBX
Yesterday Shire PLC (LON:SHP) traded -1.24% lower at 5,109.50GBX. The company’s 50-day moving average is 4,983.22GBX and its 200-day moving average is 4,511.67GBX. The last stock close price is up 10.78% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 2,529,165 shares of the stock were exchanged, up from an average trading volume of 1,960,490
See Chart Below
Shire PLC has a 52 week low of 2,707.19GBX and a 52 week high of 5,377.00GBX with a P/E ratio of 31.16 The company’s market cap is currently 0 GBX.
In addition to Goldman Sachs reporting its target price, a total of 18 firms have issued a report on the stock. The consensus target price is 73.73GBX with 6 firms rating the stock a strong buy, 16 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
General Information About Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.